Please login to the form below

Not currently logged in
Email:
Password:

Amicus

This page shows the latest Amicus news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

This year, the judges concluded that just two entrants were worthy of being shortlisted for the Innovative Product Award; Sanofi (Dupixent) and Amicus (Galafold). ... Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold),

Latest news

  • Lucid picks up rare disease and orphan drugs trophy at PMEA 2017 Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

    Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases. ... Judges said: “Amicus did a very good job for a small outfit in the start-up phase and they showed an

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Amicus Therapeutics launches Fabry treatment Galafold in Italy. Follows publication of Ministry of Health's reimbursement guidelines. ... US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Amicus gets NICE green light for Fabry drug. Oral therapy alternative Galafold approved for routine NHS use. ... The National Institute of Health and Care Excellence has given its blessing to Amicus' oral therapy for Fabry disease, a rare genetic disorder

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    SMC approves Opdivo combo as first-line skin cancer treatment. Also backs Gilead’ s Epclusa, Baxalta’ s Oncaspar, AZ’ s Lynparza and Amicus’ Galafold. ... Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    The committee gave Amicus Therapeutics' genetic disorder treatment the provisional green light, bringing UK patients one step closer to an orally administered alternative to the standard fortnightly injections. ... The regulator has agreed a confidential

More from news
Approximately 6 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Secondly, Amicus announced the purchase of Callidus Biopharma for $15m in stock and up to $115m in milestones. ... The deal gives Amicus access to Callidus' late-stage enzyme replacement therapy for Pompe disease.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics